ACXP

Acurx Pharmaceuticals, Inc.

Price Chart

No historical data available

Latest Quote

$1.44

-0.02 (-1.37%)

Current Price

Previous Close	$1.46
Open	$1.47
Day High	$1.47
Day Low	$1.42
Volume	69,739

Fetched: 2026-08-28T23:48:43

Stock Information

Shares Outstanding	4.30M
Cash Equivalents	$10.66M
Net Income	$-7.51M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$6.19M
EPS (TTM)	$-2.44
Exchange	NCM

🌐 Visit Website

Recent Price History

No history data available. Data will be fetched automatically.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

📰 Latest News

No news articles available at the moment. Check back later for updates on ACXP.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$8,091,983	$14,123,227	$14,577,768	$12,092,776
Net Non Operating Interest Income Expense	$125,445	$20,124	-	-
Operating Expense	$8,091,983	$14,123,227	$14,577,768	$12,092,776
General And Administrative Expense	$6,257,477	$8,719,391	$8,534,171	$7,338,505
Other Income Expense	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Interest Income	$125,445	$20,124	-	-
Interest Income	$125,445	$20,124	-	-
Normalized Income	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income From Continuing And Discontinued Operation	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income Common Stockholders	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income Including Noncontrolling Interests	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income Continuous Operations	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Pretax Income	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Interest Income Non Operating	$125,445	$20,124	-	-
Operating Income	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-5.32	$-17.45	$-23.00	$-22.40
Basic EPS	$-5.32	$-17.45	$-23.00	$-22.40
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
EBITDA (Bullshit earnings)	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
EBIT	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
Diluted Average Shares	$1,498,793	$808,168	$633,578	$540,820
Basic Average Shares	$1,498,793	$808,168	$633,578	$540,820
Diluted NI Availto Com Stockholders	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Research And Development	$1,834,506	$5,403,836	$6,043,597	$4,754,271
Selling General And Administration	$6,257,477	$8,719,391	$8,534,171	$7,338,505
Other Gand A	$6,257,477	$8,719,391	$8,534,171	$7,338,505
Total Unusual Items	-	-	-	$0
Total Unusual Items Excluding Goodwill	-	-	-	$0
Other Special Charges	-	-	-	-

Fetched: 2026-08-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$5,268,592	$615,121	$4,666,685	$7,315,021
Total Assets	$7,689,535	$3,857,963	$7,709,123	$9,376,706
Total Non Current Assets	$0	$0	$0	$0
Current Assets	$7,689,535	$3,857,963	$7,709,123	$9,376,706
Prepaid Assets	$85,018	$100,123	$105,776	$264,955
Receivables	$48,417	$51,127	$129,159	$0
Other Receivables	$48,417	$51,127	$129,159	-
Cash Cash Equivalents And Short Term Investments	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Cash And Cash Equivalents	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Cash Financial	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Liabilities
Total Liabilities Net Minority Interest	$2,420,943	$3,242,842	$3,042,438	$2,061,685
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$0
Current Liabilities	$2,420,943	$3,242,842	$3,042,438	$2,061,685
Payables And Accrued Expenses	$2,381,932	$2,705,212	$2,326,131	$1,518,790
Payables	$6,802	$4,787	$3,809	$29,539
Other Payable	$6,802	$4,787	$3,809	$29,539
Equity
Common Stock Equity	$5,268,592	$615,121	$4,666,685	$7,315,021
Total Equity Gross Minority Interest	$5,268,592	$615,121	$4,666,685	$7,315,021
Stockholders Equity	$5,268,592	$615,121	$4,666,685	$7,315,021
Retained Earnings	$-75,288,494	$-67,321,956	$-53,218,853	$-38,641,085
Gains Losses Not Affecting Retained Earnings	-	-	-	$-38,641,085
Other Equity Adjustments	-	-	-	$-38,641,085
Other
Ordinary Shares Number	$2,348,113	$851,534	$723,411	$581,380
Share Issued	$2,348,113	$851,534	$723,411	$581,380
Tangible Book Value	$5,268,592	$615,121	$4,666,685	$7,315,021
Invested Capital	$5,268,592	$615,121	$4,666,685	$7,315,021
Working Capital	$5,268,592	$615,121	$4,666,685	$7,315,021
Total Capitalization	$5,268,592	$615,121	$4,666,685	$7,315,021
Additional Paid In Capital	$80,554,738	$67,936,225	$57,871,070	$45,944,478
Capital Stock	$2,348	$852	$14,468	$11,628
Common Stock	$2,348	$852	$14,468	$11,628
Pensionand Other Post Retirement Benefit Plans Current	$39,011	$537,630	$716,307	$542,895
Current Accrued Expenses	$2,375,130	$2,700,425	$2,322,322	$1,489,251
Treasury Shares Number	-	-	$0	-
Total Partnership Capital	-	-	$-53,218,853	$-38,641,085

Fetched: 2026-08-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-6,787,782	$-10,383,431	$-9,800,885	$-7,542,290
Operating Activities
Operating Cash Flow	$-6,787,782	$-10,383,431	$-9,800,885	$-7,542,290
Cash Flow From Continuing Operating Activities	$-6,787,782	$-10,383,431	$-9,800,885	$-7,542,290
Operating Gains Losses	-	-	-	-
Financing Activities
Repurchase Of Capital Stock	$-1,040	$0	-	-
Issuance Of Capital Stock	$6,797,112	$6,405,757	$5,944,250	$3,695,182
Financing Cash Flow	$10,637,169	$6,615,956	$8,163,322	$3,695,195
Cash Flow From Continuing Financing Activities	$10,637,169	$6,615,956	$8,163,322	$3,695,195
Net Common Stock Issuance	$6,796,072	$6,405,757	$5,944,250	$3,695,182
Common Stock Issuance	$6,797,112	$6,405,757	$5,944,250	$3,695,182
Other
End Cash Position	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Beginning Cash Position	$3,706,713	$7,474,188	$9,111,751	$12,958,846
Changes In Cash	$3,849,387	$-3,767,475	$-1,637,563	$-3,847,095
Proceeds From Stock Option Exercised	$3,841,097	$210,199	$2,219,072	$13
Common Stock Payments	$-1,040	$0	-	-
Change In Working Capital	$-390,964	$284,089	$1,010,773	$1,248,125
Change In Payables And Accrued Expense	$-408,779	$200,404	$980,753	$1,217,776
Change In Prepaid Assets	$15,105	$5,653	$159,179	$30,349
Change In Receivables	$2,710	$78,032	$-129,159	$0
Stock Based Compensation	$1,569,720	$3,435,583	$3,766,110	$3,302,361
Net Income From Continuing Operations	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Other Non Cash Items	-	-	$559,583	$430,680
Pension And Employee Benefit Expense	-	-	-	$0
Issuance Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Issuance	-	-	-	-

Fetched: 2026-08-19